序贯TACE联合卡瑞利珠单抗与阿帕替尼新辅助治疗单发巨大肝细胞癌(NEO-START):随机对照试验研究方案
本研究为多中心、开放标签、随机3期试验,计划在7家三级医院纳入60例单发巨大(直径≥10 cm)可切除肝细胞癌患者,按1:1随机分为单纯手术组与新辅助治疗(TACE后卡瑞利珠单抗200 mg每2周一次共4周期联合阿帕替尼250 mg每日一次共2个月)后手术组,主要终点为1年无复发生存率。
要点
- 该研究评估序贯TACE、卡瑞利珠单抗与阿帕替尼新辅助治疗单发巨大可切除肝细胞癌的疗效与安全性。
- 新辅助组在随机后1周内接受TACE,随后卡瑞利珠单抗200 mg每2周一次共4周期,联合阿帕替尼250 mg每日一次共2个月。
- 主要终点为1年无复发生存率,计划样本量60例,以在1年内积累足够RFS事件达到80%把握度。
核心结论
- 本试验将研究TACE、卡瑞利珠单抗与阿帕替尼三药联合作为巨大可切除肝细胞癌新辅助策略的疗效与安全性。
研究设计与样本
- 多中心、开放标签、随机3期试验,计划在7家三级医院纳入60例单发巨大(直径≥10 cm)可切除肝细胞癌患者,按1:1随机分为单纯手术组与新辅助治疗后手术组。
主要发现
- 原文为研究方案,未报告试验结果。
关键数值与推荐
- 新辅助治疗组在随机后1周内接受TACE,随后卡瑞利珠单抗200 mg每2周一次共4周期,联合阿帕替尼250 mg每日一次共2个月。
- 新辅助治疗后接受肝切除,除非疾病评估为进展。
- 主要终点为1年无复发生存率(RFS),计划样本量60例,以在1年内积累足够RFS事件达到80%把握度。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The high recurrence rate after liver resection emphasizes the urgent need for neoadjuvant therapy in hepatocellular carcinoma (HCC) to enhance the overall prognosis for patients. Immune checkpoint inhibitors, camrelizumab combined with an anti-angiogenic tyrosine kinase inhibitor (TKI) apatinib, have emerged as a first-line treatment option for patients with unresectable HCC, yet its neoadjuvant application in combination with transarterial chemoembolization (TACE) in HCC remains unexplored. Therefore, this study aims to investigate the efficacy and safety of sequential TACE, camrelizumab, and apatinib as a neoadjuvant therapy for single, huge HCC. METHODS: This multi-center, open-label randomized phase 3 trial will be conducted at 7 tertiary hospitals. Patients with single huge (≥ 10 cm in diameter), resectable HCC will be randomly assigned in a 1:1 ratio to arm of surgery alone or arm of neoadjuvant therapy followed by surgery. In the neoadjuvant therapy group, patients will receive TACE within 1 week after randomization, followed by camrelizumab (200 mg q2w, 4 cycles), along with apatinib (250 mg qd, 2 months). Patients will receive liver resection after neoadjuvant therapy unless the disease is assessed as progressive. The primary outcome is recurrence-free survival (RFS) at 1 year. The planned sample size of 60 patients will be calculated to permit the accumulation of sufficient RFS events in 1 year to achieve 80% power for the RFS primary endpoint. DISCUSSION: Synergistic effects provided by multimodality therapy of locoregional treatment, TKI, and anti-programmed cell death 1 inhibitor significantly improved overall survival for patients with unresectable HCC. Our trial will investigate the efficacy and safety of the triple combination of TACE, camrelizumab, and apatinib as a neoadjuvant strategy for huge, resectable HCC. TRIAL REGISTRATION: www.chitr.org.cn ChiCTR2300078086. Registered on November 28, 2023. Start recruitment: 1st January 2024. Expected completion of recruitment: 15th June 2025.
引用
- Hao Y, Xie F, Zhou Y, et al. Neoadjuvant therapy of sequential TACE, camrelizumab, and apatinib for single huge hepatocellular carcinoma (NEO-START): study protocol for a randomized controlled trial. Trials. 2024. PMID: 39030637. doi:10.1186/s13063-024-08340-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。